TL;DR
In a trademark dispute between two pharmaceutical companies, the Supreme Court affirmed that under the Intellectual Property Code of the Philippines, trademark ownership is acquired through registration, not prior use. Natrapharm, Inc., as the first to register the trademark “ZYNAPSE”, rightfully prevented Zuneca Pharmaceutical from using the confusingly similar mark “ZYNAPS” even though Zuneca had used its mark earlier. However, because Zuneca was deemed a ‘prior user in good faith,’ the Court limited Natrapharm’s remedies, allowing Zuneca to continue using “ZYNAPS” but mandated both companies to clearly differentiate their products’ uses on packaging to avoid potentially dangerous medication errors among consumers.
First to File, First in Right? Unpacking Trademark Ownership in the Philippine Pharmaceutical Market
In the bustling marketplace of pharmaceuticals, brand recognition is critical. This case between Zuneca Pharmaceutical and Natrapharm, Inc. highlights a pivotal question: In the Philippines, who truly owns a trademark – the first to use it, or the first to register it? Both companies marketed medicines with strikingly similar names, “ZYNAPS” and “ZYNAPSE”, leading to a legal battle over trademark infringement. The heart of the dispute lies in understanding how Philippine law defines and protects trademark ownership, especially when public health is at stake.
The Supreme Court, in its decision, firmly grounded trademark ownership in the principle of registration under the Intellectual Property Code (IP Code). Justice Caguioa, writing for the Court, meticulously traced the evolution of trademark law in the Philippines, starting from the Spanish Royal Decree of 1888, through Act No. 666 and Republic Act No. 166, culminating in the IP Code. The analysis underscored a significant shift: from a system where ownership was rooted in prior use to one where registration is the cornerstone of trademark rights. Section 122 of the IP Code is unequivocal: “Rights in a mark shall be acquired through registration made validly in accordance with the provisions of this law.”
The Court acknowledged Zuneca’s argument as the prior user of “ZYNAPS” since 2004, predating Natrapharm’s “ZYNAPSE” registration in 2007. Zuneca invoked precedents like Berris Agricultural Co., Inc. v. Abyadang and E.Y. Industrial Sales, Inc. v. Shen Dar Electricity and Machinery Co., Ltd., arguing that prior use established their ownership. However, the Supreme Court distinguished these cases, clarifying that while these earlier decisions considered prior use, they were inconsistent with the prevailing IP Code regime that prioritizes registration. The Court explicitly rectified statements in Berris that suggested ownership is acquired through registration and actual use, clarifying that under the IP Code, ownership is acquired solely by registration.
However, the Court recognized a crucial caveat: the concept of a ‘prior user in good faith’ as outlined in Section 159.1 of the IP Code. This provision states that a registered mark has no effect against a person who, in good faith, was using a similar mark before the filing or priority date of the registered mark. While Natrapharm, as the registered owner of “ZYNAPSE”, generally holds the exclusive right to prevent others from using confusingly similar marks, Zuneca, as a prior user in good faith of “ZYNAPS”, was deemed exempt from trademark infringement liability. This exemption, however, is not without limitations; Zuneca’s right to use “ZYNAPS” is tied to its existing business and cannot be transferred independently.
Despite finding Zuneca not liable for infringement due to its status as a prior user in good faith, the Court recognized the significant public health risk posed by the confusingly similar drug names. To mitigate potential medication errors, the Court mandated both Zuneca and Natrapharm to include prominent, plain-language statements on their product packaging clearly differentiating the medical conditions each drug treats and explicitly stating what each drug is not intended to treat. This measure underscores the Court’s balancing act: upholding the registration-based trademark system while safeguarding public health.
The ruling in Zuneca Pharmaceutical v. Natrapharm, Inc. reinforces the Philippines’ adherence to the first-to-file rule in trademark ownership. It clarifies that while prior use is no longer the determinant of ownership, the IP Code acknowledges and protects ‘prior users in good faith’ to a limited extent. The case also serves as a stark reminder of the critical importance of trademark registration for businesses, especially in sensitive sectors like pharmaceuticals, and highlights the judiciary’s role in balancing intellectual property rights with broader public interest concerns.
| What was the key issue in this case? | The central issue was determining trademark ownership between two pharmaceutical companies using confusingly similar marks for different medicines: Zuneca (prior user of “ZYNAPS”) and Natrapharm (registered owner of “ZYNAPSE”). |
| What did the Supreme Court decide? | The Supreme Court ruled in favor of Natrapharm, affirming that trademark ownership in the Philippines is acquired through registration under the Intellectual Property Code, not merely by prior use. |
| Was Zuneca found liable for trademark infringement? | No, Zuneca was not found liable for trademark infringement because it was considered a ‘prior user in good faith,’ allowing it to continue using its mark despite Natrapharm’s registration. |
| What is the ‘first-to-file’ rule? | The ‘first-to-file’ rule means that in the Philippines, the first entity to register a trademark generally obtains ownership and exclusive rights to that mark, regardless of who used it first. |
| What is the ‘prior user in good faith’ exception? | Section 159.1 of the IP Code provides a limited exception, protecting those who were already using a mark in good faith before someone else registered a confusingly similar mark. This protection allows continued use but does not confer full ownership. |
| Why was this case significant for public health? | Because the case involved medicines with similar names but different uses, the potential for medication errors and harm to public health was a major concern, leading the Court to mandate clear labeling for both products. |
| What is the practical takeaway for businesses? | Businesses in the Philippines should prioritize trademark registration to secure ownership rights. While prior use offers limited protection, registration is the definitive path to exclusive trademark rights. |
For inquiries regarding the application of this ruling to specific circumstances, please contact Atty. Gabriel Ablola through gaboogle.com or via email at connect@gaboogle.com.
Disclaimer: This analysis is provided for informational purposes only and does not constitute legal advice. For specific legal guidance tailored to your situation, please consult with a qualified attorney.
Source: ZUNECA PHARMACEUTICAL, AKRAM ARAIN AND/OR VENUS ARAIN, M.D., AND STYLE OF ZUNECA PHARMACEUTICAL VS. NATRAPHARM, INC., G.R. No. 211850, September 08, 2020

Leave a Reply